The need for treatment strategies targeting complex structural heart and obstructive epicardial coronary artery disease (CAD) is rapidly growing. The 2019 societal scientific sessions included novel research and landmark presentations on less invasive valvular and safer complex coronary interventions in the aforementioned populations, in hopes of improving patient outcomes and expanding treatment indications. Transcatheter aortic valve replacement (TAVR), percutaneous mitral and tricuspid valve therapy, and complex coronary interventions, were the focus of important clinical trials and registry data.
Structural heart disease: the year in valvular and complex coronary intervention trials
Are the dynamic changes of the aortic root determinant for thrombosis or leaflet degeneration after transcatheter aortic valve replacement?
Mitral regurgitation after transcatheter aortic valve replacement
Mitral regurgitation: lessons learned from COAPT and MITRA-Fr
The tricuspid valve in review: anatomy, pathophysiology and echocardiographic assessment with focus on functional tricuspid regurgitation
Transthoracic versus intra-operative transesophageal echocardiography in right heart assessment
Tricuspid regurgitation and in-hospital outcomes after transcatheter aortic valve replacement in high-risk patients
Relationship between compliance and pulmonary vascular resistance in pulmonary arterial hypertension
Early failure of mitral valve repair with anterior leaflet pericardial patch augmentation in rheumatic and radiation-induced valvulitis
Inappropriate pacing due to T-wave oversensing
Cardiovascular implantable electronic device-related tricuspid regurgitation: a multidisciplinary team approach
Disclosure:
The series “Novel Concepts in Cardiopulmonary and Structural Heart Disease” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. Christos G. Mihos served as the unpaid Guest Editor for the series.